You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Baltimore, Maryland

  • Digestive System Surgical Procedures


The purpose of the study is to evaluate the efficacy of Seprafilm in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm occurring within 30 days postoperatively, and the incidence of abdominopelvic abscess within 6 months postoperatively.


Inclusion Criteria: - Patients who were undergoing colon and/or rectal resections and/or adhesiolysis for treatment of bowel obstruction Exclusion Criteria: - Patients with any medical condition or disease where 5-year survival was not expected - Patients undergoing laparoscopy - Patients undergoing surgery for treatment of acute abdominal trauma - Patients with an abscess (abdominal or pelvic) present during the initial surgery - Patients with a history of pulmonary embolus or deep vein thrombosis (DVT) within 1 year of surgery

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

Official Title:

A Prospective, Randomized, Multicenter, Controlled Evaluation of the Efficacy and Safety of Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:

85 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:


Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification: S

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Study Dates

Start Date:June 1998
Completion Date:August 2003
Verification Date:March 2015
Last Changed Date:March 11, 2015
First Received Date:August 15, 2005

Study Outcomes

Outcome Type:Primary Outcome
Measure:Reducing the incidence of bowel obstruction following intestinal resection, and subsequently, reducing the number of re-operations
Safety Issues:False

Study Interventions

Intervention Type:Device
Name:Seprafilm Bioresorbable Membrane

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Genzyme, a Sanofi Company

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.